Cargando…
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
INTRODUCTION: The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT...
Autores principales: | Arriola, Edurne, González-Cao, María, Domine, Manuel, De Castro, Javier, Cobo, Manuel, Bernabé, Reyes, Navarro, Alejandro, Sullivan, Ivana, Trigo, José Manuel, Mosquera, Joaquín, Crama, Leonardo, Isla, Dolores |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098752/ https://www.ncbi.nlm.nih.gov/pubmed/35032007 http://dx.doi.org/10.1007/s40487-021-00182-0 |
Ejemplares similares
-
Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis
por: Arriola, Edurne, et al.
Publicado: (2021) -
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
por: Isla, Dolores, et al.
Publicado: (2023) -
First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020) -
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023) -
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023)